Opposing consequences of signaling through egf family members: Escape from ctls could be a bait for nk cells

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1200-1201

  Kiessling, Rolf ^a   Okita, Riki ^a   Mougiakakos, Dimitrios ^a,b   Mao, Yumeng ^a   Sarhan, Dhifaf ^a   Wennerberg, Erik ^a   Seliger, Barbara ^c   Lundqvist, Andreas ^a   Mimura, Kousaku ^d   Kono, Koji ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

EGF receptors; Immune escape; MHC Class I; MICA B; NK cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; NATURAL KILLER CELL; ONCOGENE; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84886944174     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20685     Document Type: Article

References (10)

1. Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012; 61:249-54; PMID:22120755; http://dx.doi.org/10.1007/s00262-011-1153-9.
2. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100:8933-8; PMID:12853564; http://dx.doi.org/10.1073/pnas.1537685100.
3. Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, et al. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009; 58:653-64; PMID:18820911; http://dx.doi.org/10.1007/s00262-008-0587-1.
4. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004; 64:215-20; PMID:14729627; http://dx.doi.org/10.1158/0008-5472.CAN-2522-2.
5. Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 2011; 128:390-401; PMID:20715101; http://dx.doi.org/10.1002/ijc.25613.
6. Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes J P, Hueman MT, et al. The impact of HER2/ neu expression level on response to the E75 vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15:2895-904; PMID:19351776; http://dx.doi.org/10.1158/1078-0432.CCR-08-1126.
7. Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, et al. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012; 188:2136-45; PMID:22301547; http://dx.doi.org/10.4049/jimmu-nol.1102237.
8. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9; PMID:10426993; http://dx.doi.org/10.1126/science.285.5428.727.
9. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176:5108-16; PMID:16585609.
10. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.org/10.1038/nature03884.